FDA Seeks to Ban Concentrated 7-OH Opioid Products, Citing Risks to Youth and Public Health

In a move aimed at curbing opioid misuse, the U.S. Food and Drug Administration announced plans to classify 7-hydroxymitragynine (7-OH), a powerful derivative of the kratom plant, as a controlled substance. According to a July 29 release from the FDA, the agency has recommended the Drug Enforcement Administration begin scheduling the substance under the Controlled Substances Act due to its high abuse potential and increasing presence in unregulated consumer products.

While the natural kratom leaf remains unregulated, the FDA’s action targets synthesized or concentrated forms of 7-OH, which bind strongly to opioid receptors and may exceed morphine in potency. These substances are often found in items like gummies, drink mixes, and vape liquids—frequently sold at gas stations, convenience stores, and online retailers. Many of these products are misleadingly labeled and marketed in youth-friendly formats, raising alarm among federal health officials.

The FDA emphasized that 7-OH is not approved for any medical use, is illegal in dietary supplements, and cannot lawfully be added to food products. To protect consumers, especially teenagers and children, the agency issued warning letters in June to seven companies illegally selling 7-OH-containing products. In addition, it has launched a public education campaign and released a healthcare provider advisory to raise awareness of the risks associated with these products.

This latest action reflects the broader strategy of the current federal administration to address drug abuse and protect public health. Health and Human Services Secretary Robert F. Kennedy Jr., serving under President Donald J. Trump, signaled the administration’s intent to take preemptive steps against emerging opioid threats. The recommendation now goes to the DEA, which will review the evidence, collect public comments, and decide on official scheduling.

Article by multiple contributors, based upon information from U.S. Food and Drug Administration press release

---